Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

APOBEC3G (Q9HC16) - Overview - Molecular Target Synopsis

Protein


APOBEC3G, DNA dC->dU-editing enzyme APOBEC-3G
Enzyme Classification 3.5.4.-
UniProt Q9HC16

Also Known as ABC3G_HUMAN, APOBEC3G

DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits potent antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. Exhibits antiviral activity also against simian immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV). May inhibit the mobility of LTR and non-LTR retrotransposons. Homodimer. Homooligomer. Can bind RNA to form ribonucleoprotein complexes of high-molecular-mass (HMM) or low-molecular-mass (LMM). HMM is inactive and heterogeneous in protein composition because of binding nonselectively to cellular RNAs, which in turn are associated with variety of cellular proteins. The LMM form which is enzymatically active has few or no RNAs associated. Its ability to form homooligomer is distinct from its ability to assemble into HMM. Interacts with APOBEC3B, APOBEC3F, MOV10, AGO2, EIF4E, EIF4ENIF1, DCP2 and DDX6 in an RNA-dependent manner. Interacts with AGO1, AGO3 and PKA/PRKACA.

6K3J
SOLUTION STRUCTURE OF APOBEC3G-CD2 WITH SSDNA, PRODUCT A
RCSB/PDB
Inspect Structure
See all 3D Structures for APOBEC3G

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
384ENSG00000239713ENST00000452957, ENST00000407997ENSP00000413376, ENSP00000385057Q9HC16-1
79Q9HC16-3

Sub-cellular localization


UniProt: APOBEC3G is active in the following subcellular-locations: cytoplasm, nucleus, p-body.
GO terms: APOBEC3G is active in the following subcellular-locations: apolipoprotein B mRNA editing enzyme complex, cytoplasm, cytosol, nucleus, P-body, ribonucleoprotein complex.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project APOBEC3G has gain in 0 cell-lines, loss in 1 cell-lines and no signal in 1003 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: HT29, MALME_3M, SK_MEL_28

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: COR-L26, CCRF-SB, LP-1

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: HMEC, GM12878, SK-N-SH

(see details)

3D Structures


For APOBEC3G there are:
16 structures (25 chains) solved
1 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


APOBEC3G has been screened with 1024 compounds (1085 bioactivities), 2 compounds have bioactivities that show binding affinity of <= 500nM (2 bioactivities). (see details)